Last 7 days
-1.8%
Last 30 days
3.9%
Last 90 days
-6.9%
Trailing 12 Months
5.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 401.1B | 94.9B | -3.25% | -11.17% | 22.36 | 4.23 | 1.25% | -14.07% |
LLY | 302.8B | 28.5B | 2.15% | 17.94% | 48.48 | 10.61 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -3.99% | 33.34% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.5B | 100.3B | -4.70% | -21.30% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 143.9B | 46.2B | -5.09% | -4.47% | 22.74 | 3.12 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.6B | 4.5B | -7.51% | -10.48% | -32.41 | 1.02 | 7.56% | -104.06% |
SMALL-CAP | ||||||||
PRVB | 2.1B | 2.8M | 167.83% | 203.17% | -19.6 | 748.91 | 245.83% | 12.43% |
PCRX | 1.8B | 666.8M | -7.47% | -48.23% | 112.99 | 2.7 | 23.14% | -62.10% |
TLRY | 1.6B | 602.5M | -7.75% | -62.41% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -20.50% | -75.95% | -0.29 | 1.93 | -31.50% | -634.70% |
AERI | 753.2M | 213.9M | 0.39% | 48.49% | -20.6 | 3.52 | 105.41% | 78.04% |
CRON | 738.3M | 114.5M | -10.60% | -51.38% | -4.38 | 6.45 | 27.90% | 57.40% |
TBPH | 686.2M | 51.3M | 3.85% | 5.52% | 0.79 | 13.36 | -7.17% | 537.32% |
NGM | 311.2M | 55.3M | -19.49% | -76.66% | -1.91 | 5.63 | -29.00% | -35.18% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -0.6% | 51,346,000 | 51,643,000 | 52,386,000 | 54,250,000 | 55,311,000 |
Operating Expenses | -20.8% | 148,361,000 | 187,393,000 | 227,549,000 | 266,644,000 | 313,095,000 |
S&GA Expenses | -9.2% | 67,073,000 | 73,900,000 | 78,922,000 | 87,867,000 | 99,296,000 |
R&D Expenses | -20.7% | 63,392,000 | 79,917,000 | 113,789,000 | 149,311,000 | 193,657,000 |
EBITDA | -466.3% | -86,446,000 | 23,601,000 | -6,096,000 | -98,876,000 | - |
EBITDA Margin | -468.4% | -1.68 | 0.46 | -0.12 | -1.82 | - |
Earnings Before Taxes | -121.2% | -92,815,000 | -41,962,000 | -81,856,000 | -126,285,000 | -199,577,000 |
EBT Margin | -122.5% | -1.81 | -0.81 | -1.56 | -2.68 | - |
Interest Expenses | -90.3% | 6,369,000 | 65,563,000 | 66,154,000 | 65,882,000 | 46,889,000 |
Net Income | 2.5% | 872,132,000 | 850,460,000 | -101,479,000 | -145,693,000 | -199,426,000 |
Net Income Margin | 3.1% | 16.99 | 16.47 | -1.94 | -2.69 | - |
Free Cahsflow | -77.5% | -186,991,000 | -105,370,000 | -128,679,000 | -164,062,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -20.4% | 607 | 763 | 361 | 355 | 375 |
Current Assets | -30.9% | 353 | 512 | 155 | 205 | 250 |
Cash Equivalents | -28.6% | 299 | 419 | 87.00 | 94.00 | 90.00 |
Net PPE | -0.1% | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 |
Current Liabilities | -79.8% | 29.00 | 142 | 33.00 | 44.00 | 59.00 |
Shareholder's Equity | -8.1% | 442 | 481 | -338 | - | - |
Retained Earnings | -1.2% | -853 | -843 | -1,760 | -1,751 | -1,726 |
Additional Paid-In Capital | -2.2% | 1,296 | 1,324 | 1,410 | 1,401 | 1,387 |
Shares Outstanding | -3.2% | 65.00 | 67.00 | 76.00 | 76.00 | 74.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -77.5% | -186 | -105 | -128 | -164 | -207 |
Share Based Compensation | -20.1% | 40.00 | 50.00 | 56.00 | 61.00 | 62.00 |
Cashflow From Investing | 2.5% | 1,154 | 1,126 | 14.00 | 43.00 | 124 |
Cashflow From Financing | -4.9% | -758 | -723 | -3.44 | 102 | 92.00 |
Buy Backs | -65.8% | 129 | 376 | - | - | - |
95.4%
91.9%
57.7%
Y-axis is the maximum loss one would have experienced if Theravance Biopharma was unfortunately bought at previous high price.
-6.6%
-16.6%
-23.5%
FIve years rolling returns for Theravance Biopharma.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 43.61 | 659,033 | 1,778,030 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | 28,148 | 291,148 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -2.47 | 166,000 | 2,343,000 | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | 84,187 | 872,187 | -% |
2023-02-15 | JANE STREET GROUP, LLC | reduced | -23.06 | -286,152 | 1,639,850 | -% |
2023-02-15 | Point72 Middle East FZE | new | - | 40,942 | 40,942 | -% |
2023-02-14 | MILLENNIUM MANAGEMENT LLC | added | 3.83 | 982,000 | 7,579,000 | -% |
2023-02-14 | Irenic Capital Management LP | new | - | 19,084,500 | 19,084,500 | 9.15% |
2023-02-14 | Bank of New York Mellon Corp | added | 2.98 | 290,107 | 2,374,110 | -% |
2023-02-14 | Nuveen Asset Management, LLC | added | 43.07 | 1,041,000 | 2,828,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | madison avenue partners, lp | 10.4% | 7,012,226 | SC 13G/A | |
Feb 14, 2023 | orbimed advisors llc | 0% | 0 | SC 13G/A | |
Feb 13, 2023 | baupost group llc/ma | 16.95% | 11,419,226 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.25% | 5,558,839 | SC 13G/A | |
Jan 30, 2023 | barclays plc | 5.00% | 3,371,298 | SC 13G | |
Sep 20, 2022 | gsk plc | 0.0% | 0 | SC 13D/A | |
Jun 16, 2022 | weiss asset management lp | 8.09% | 6,157,360 | SC 13G | |
Apr 21, 2022 | odre 2005 slu | 5.5% | 4,108,318 | SC 13G | |
Feb 14, 2022 | point72 asset management, l.p. | 0.2% | 145,100 | SC 13G/A | |
Feb 14, 2022 | madison avenue partners, lp | 9.0% | 6,648,025 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.83 -92.11% | 1.14 -89.16% | 2.65 -74.81% | 5.86 -44.30% | 7.19 -31.65% |
Current Inflation | 0.78 -92.59% | 1.05 -90.02% | 2.39 -77.28% | 5.20 -50.57% | 6.34 -39.73% |
Very High Inflation | 0.71 -93.25% | 0.95 -90.97% | 2.09 -80.13% | 4.41 -58.08% | 5.33 -49.33% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 17, 2023 | PRE 14A | PRE 14A | |
Mar 16, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 8-K | Current Report | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-14 | GRAHAM RICHARD A | sold | -23,973 | 10.32 | -2,323 | svp, research & development |
2023-03-09 | Farnum Rhonda | sold | -40,800 | 10.2 | -4,000 | svp, comm & medical affairs |
2023-03-06 | GRAHAM RICHARD A | sold | -23,346 | 10.05 | -2,323 | svp, research & development |
2023-03-01 | Sawaf Aziz | acquired | - | - | 80,000 | svp & chief financial officer |
2023-03-01 | Grimaud Brett A. | acquired | - | - | 75,000 | svp, gen counsel and secretary |
2023-03-01 | GRAHAM RICHARD A | acquired | - | - | 75,000 | svp, research & development |
2023-03-01 | Farnum Rhonda | acquired | - | - | 75,000 | svp, comm & medical affairs |
2023-03-01 | Winningham Rick E | acquired | - | - | 330,000 | chief executive officer |
2023-02-26 | GRAY SUSANNAH | acquired | - | - | 11,819 | - |
2023-02-20 | Grimaud Brett A. | sold (taxes) | -106,467 | 10.44 | -10,198 | svp, gen counsel and secretary |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Total revenue | $ 51,346 | $ 55,311 | $ 71,857 |
Expenses: | |||
Research and development (1) | 63,392 | 193,657 | 260,953 |
Selling, general and administrative (1) | 67,073 | 99,296 | 108,531 |
Restructuring and related expenses (1) | 12,838 | 20,142 | |
Total expenses | 143,303 | 313,095 | 369,484 |
Loss from operations | (91,957) | (257,784) | (297,627) |
Interest expense | (6,369) | (8,547) | (8,547) |
Loss on extinguishment of debt | (3,034) | ||
Interest income and other income, net | 8,545 | 1,109 | 2,831 |
Loss from continuing operations before income taxes | (92,815) | (265,222) | (303,343) |
Provision for income tax (expense) benefit | (9) | 151 | 8,520 |
Net loss from continuing operations | (92,824) | (265,071) | (294,823) |
Income from discontinued operations before income taxes | 1,143,930 | 65,645 | 16,806 |
Provision for income tax expense | (178,974) | ||
Net income from discontinued operations | 964,956 | 65,645 | 16,806 |
Net income (loss) | $ 872,132 | $ (199,426) | $ (278,017) |
Net income (loss) per share: | |||
Continuing operations - basic | $ (1.26) | $ (3.82) | $ (4.73) |
Continuing operations - diluted | (1.26) | (3.82) | (4.73) |
Discontinued operations - basic | 13.11 | 0.95 | 0.27 |
Discontinued operations - diluted | 13.11 | 0.95 | 0.27 |
Net income (loss) - basis | 11.85 | (2.87) | (4.46) |
Net income (loss) - diluted | $ 11.85 | $ (2.87) | $ (4.46) |
Shares used to compute basis and diluted net income (loss) per share | 73,591 | 69,461 | 62,345 |
Shares used to compute basis and diluted net income (loss) per share | 73,591 | 69,461 | 62,345 |
Total share-based compensation expense | $ 39,734 | $ 62,061 | $ 62,976 |
Research and development | |||
Expenses: | |||
Restructuring and related expenses (1) | 5,900 | 10,600 | |
Net income (loss) per share: | |||
Total share-based compensation expense | 12,888 | 25,634 | 31,294 |
Selling, general and administrative | |||
Expenses: | |||
Restructuring and related expenses (1) | 6,900 | 9,500 | |
Net income (loss) per share: | |||
Total share-based compensation expense | 19,848 | 28,065 | 31,682 |
Restructuring and related expenses | |||
Net income (loss) per share: | |||
Total share-based compensation expense | 6,998 | 8,362 | |
Viatris collaboration agreement | |||
Revenue: | |||
Total revenue | 48,624 | 43,848 | 43,893 |
Viatris royalties (Non-US) | |||
Revenue: | |||
Total revenue | 30 | ||
Collaboration revenue | |||
Revenue: | |||
Total revenue | 192 | $ 11,463 | 26,464 |
Licensing revenue | |||
Revenue: | |||
Total revenue | $ 2,500 | $ 1,500 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 298,172 | $ 89,959 |
Short-term marketable securities | 29,312 | 83,506 |
Receivables from collaborative arrangements | 16,785 | 14,065 |
Prepaid clinical and development services | 1,513 | 10,245 |
Other prepaid and current assets | 7,682 | 8,561 |
Amounts due from TRC, LLC (Discontinued operations) | 43,534 | |
Total current assets | 353,464 | 249,870 |
Property and equipment, net | 11,875 | 13,657 |
Operating lease assets | 40,126 | 39,690 |
Future contingent milestone and royalty assets | 194,200 | |
Restricted cash | 836 | 837 |
Other assets | 6,899 | 3,228 |
Equity in net assets of TRC, LLC (Discontinued operations) | 67,537 | |
Total assets | 607,400 | 374,819 |
Current liabilities: | ||
Accounts payable | 1,554 | 3,098 |
Accrued personnel-related expenses | 10,314 | 12,796 |
Accrued clinical and development expenses | 4,932 | 17,010 |
Accrued general and administrative expenses | 4,020 | 2,898 |
Operating lease liabilities | 6,753 | 503 |
Deferred revenue | 24 | 98 |
Other accrued liabilities | 1,118 | 1,304 |
Accrued interest payable | 1,246 | |
Current portion of non-recourse notes due 2035, net (Discontinued operations) | 16,940 | |
Accrued interest payable (Discontinued operations) | 2,694 | |
Total current liabilities | 28,715 | 58,587 |
Long-term operating lease liabilities | 45,407 | 52,681 |
Future royalty payment contingency | 25,438 | |
Long-term deferred revenue | 192 | 310 |
Unrecognized tax benefits | 64,191 | 240 |
Other long-term liabilities | 1,657 | 2,180 |
Convertible senior notes due 2023, net | 228,035 | |
Non-recourse notes due 2035, net | 371,359 | |
Commitments and contingencies | ||
Shareholders' Equity (Deficit) | ||
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding | ||
Ordinary shares, $0.00001 par value: 200,000 shares authorized; [65,227] and 74,435 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 1 | 1 |
Additional paid-in capital | 1,295,725 | 1,387,469 |
Accumulated other comprehensive loss | (15) | |
Accumulated deficit | (853,911) | (1,726,043) |
Total shareholders' equity (deficit) | 441,800 | (338,573) |
Total liabilities and shareholders' equity (deficit) | $ 607,400 | $ 374,819 |